AU708032B2 - Azetidinone derivatives for the treatment of atherosclerosis - Google Patents
Azetidinone derivatives for the treatment of atherosclerosis Download PDFInfo
- Publication number
- AU708032B2 AU708032B2 AU63050/96A AU6305096A AU708032B2 AU 708032 B2 AU708032 B2 AU 708032B2 AU 63050/96 A AU63050/96 A AU 63050/96A AU 6305096 A AU6305096 A AU 6305096A AU 708032 B2 AU708032 B2 AU 708032B2
- Authority
- AU
- Australia
- Prior art keywords
- oxoazetidin
- diastereoisomer
- acetamide
- ylacetamide
- propionamide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/085—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
- C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D205/06—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D205/08—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams
- C07D205/09—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4
- C07D205/095—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with one oxygen atom directly attached in position 2, e.g. beta-lactams with a sulfur atom directly attached in position 4 and with a nitrogen atom directly attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9513442 | 1995-07-01 | ||
| GBGB9513442.5A GB9513442D0 (en) | 1995-07-01 | 1995-07-01 | Novel compounds |
| GBGB9515056.1A GB9515056D0 (en) | 1995-07-22 | 1995-07-22 | Novel compounds |
| GB9515056 | 1995-07-22 | ||
| GBGB9515206.2A GB9515206D0 (en) | 1995-07-25 | 1995-07-25 | Novel compounds |
| GB9515206 | 1995-07-25 | ||
| GB9516985 | 1995-08-18 | ||
| GBGB9516985.0A GB9516985D0 (en) | 1995-08-18 | 1995-08-18 | Novel compounds |
| GBGB9525132.8A GB9525132D0 (en) | 1995-12-08 | 1995-12-08 | Novel compounds |
| GB9525132 | 1995-12-08 | ||
| GB9608650 | 1996-04-26 | ||
| GBGB9608651.7A GB9608651D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| GBGB9608650.9A GB9608650D0 (en) | 1996-04-26 | 1996-04-26 | Novel compounds |
| GB9608651 | 1996-04-26 | ||
| PCT/EP1996/002765 WO1997002242A1 (fr) | 1995-07-01 | 1996-06-20 | Derives de l'azetidinone pour le traitement de l'atherosclerose |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU6305096A AU6305096A (en) | 1997-02-05 |
| AU708032B2 true AU708032B2 (en) | 1999-07-29 |
Family
ID=27562921
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU63050/96A Ceased AU708032B2 (en) | 1995-07-01 | 1996-06-20 | Azetidinone derivatives for the treatment of atherosclerosis |
Country Status (23)
| Country | Link |
|---|---|
| EP (1) | EP0840725A1 (fr) |
| JP (1) | JP2002515852A (fr) |
| KR (1) | KR19990028630A (fr) |
| CN (1) | CN1197452A (fr) |
| AP (1) | AP728A (fr) |
| AU (1) | AU708032B2 (fr) |
| BG (1) | BG102214A (fr) |
| BR (1) | BR9609445A (fr) |
| CA (1) | CA2225627A1 (fr) |
| CZ (1) | CZ422197A3 (fr) |
| EA (1) | EA199800109A1 (fr) |
| HU (1) | HUP9901153A3 (fr) |
| IL (1) | IL122650A0 (fr) |
| MA (1) | MA23922A1 (fr) |
| MX (1) | MX9800186A (fr) |
| NO (1) | NO976158L (fr) |
| NZ (1) | NZ311684A (fr) |
| OA (1) | OA10648A (fr) |
| PE (1) | PE8998A1 (fr) |
| PL (1) | PL324240A1 (fr) |
| SK (1) | SK178497A3 (fr) |
| TR (1) | TR199701762T1 (fr) |
| WO (1) | WO1997002242A1 (fr) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997021675A1 (fr) * | 1995-12-08 | 1997-06-19 | Smithkline Beecham Plc | Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose |
| EP0915843A1 (fr) * | 1996-04-26 | 1999-05-19 | Smithkline Beecham Plc | Derives azetidinones destines au traitement de l'atherosclerose |
| GB9608649D0 (en) * | 1996-04-26 | 1996-07-03 | Smithkline Beecham Plc | Novel compounds |
| WO2001060805A1 (fr) | 2000-02-16 | 2001-08-23 | Smithkline Beecham P.L.C. | Derives de pyrimidine-4-one utilises comme inhibiteurs de ldl-pla¿2? |
| GB0024808D0 (en) | 2000-10-10 | 2000-11-22 | Smithkline Beecham Plc | Novel compounds |
| BRPI0721697A2 (pt) | 2007-05-11 | 2014-08-05 | Univ Jefferson | " métodos para tratar e/ou prevenir uma doença ou distúrbio neurodegenerativo em um indivíduo, para tratar e/ou prevenir um indivíduo com ou em risco de demência vascular, para tratar e/ou prevenir uma doença ou distúrbio associado com uma barreira hematoencefálica anormal em um indivíduo, para diminuir o acúmulo beta amilóide no cérebro de um indivíduo, para tratar e/ou prevenir mal de alzheimer em um indivíduo e para prevenir ou reduzir o risco de desenvolver mal de alzhheimer, e, uso de um agente que inibe a expressão e/ou atividade da proteína lp-pla2." |
| US8962633B2 (en) | 2007-05-11 | 2015-02-24 | Thomas Jefferson University | Methods of treatment and prevention of metabolic bone diseases and disorders |
| JP5437996B2 (ja) | 2007-05-11 | 2014-03-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 皮膚潰瘍の治療方法 |
| MX2013006342A (es) | 2010-12-06 | 2013-08-26 | Glaxo Group Ltd | Compuestos de pirimidinona para usarse en el tratamiento de enfermedades o afecciones mediadas por fosfolipasa asociada con lipoproteinas a2 (lp-pla2). |
| ES2847883T3 (es) | 2010-12-17 | 2021-08-04 | Glaxo Group Ltd | Uso de inhibidores de LP-PLA2 en el tratamiento y prevención de enfermedades oculares |
| EP2725024A4 (fr) | 2011-06-27 | 2014-12-03 | Shanghai Inst Materia Medica | Composé hétérocyclique azole, procédé de préparation, composition pharmaceutique et utilisation |
| KR20140059203A (ko) | 2011-07-27 | 2014-05-15 | 글락소 그룹 리미티드 | 2,3-디히드로이미다조[1,2-c]피리미딘-5(1h)-온 화합물의 lp-pla2 억제제로서의 용도 |
| AU2012288865B2 (en) | 2011-07-27 | 2015-10-01 | Glaxo Group Limited | Bicyclic pyrimidone compounds |
| JP2016505053A (ja) | 2013-01-25 | 2016-02-18 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ｌｐ‐ＰＬＡ２の阻害剤としての二環式ピリミドン化合物 |
| CA2899124A1 (fr) | 2013-01-25 | 2014-07-31 | Glaxosmithkline Intellectual Property Development Limited | Composes |
| AU2014209949B2 (en) | 2013-01-25 | 2016-09-08 | Glaxosmithkline Intellectual Property Development Limited | 2,3-dihydroimidazol(1,2-c)pyrimidin-5(1h)-one based lipoprotein-associated phospholipase a2 (Lp-PLA2) inhibitors |
| WO2016012917A1 (fr) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2 |
| WO2016012916A1 (fr) | 2014-07-22 | 2016-01-28 | Glaxosmithkline Intellectual Property Development Limited | Dérivés 1,2,3,5-tétrahydro-imidazo [1,2-c]pyrimidine utiles pour le traitement de maladies et de troubles médiés par la lp-pla2 |
| BR112022008786A2 (pt) | 2019-11-09 | 2022-07-26 | Shanghai Simr Biotechnology Co Ltd | Composto, composição, uso do composto ou da composição, e, método para tratar ou prevenir uma complicação diabética, doença relacionada à neuroinflamação ou aterosclerose |
| CN115304620A (zh) | 2021-05-07 | 2022-11-08 | 上海赛默罗生物科技有限公司 | 嘧啶酮衍生物、其制备方法、药物组合物和用途 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4680391A (en) * | 1983-12-01 | 1987-07-14 | Merck & Co., Inc. | Substituted azetidinones as anti-inflammatory and antidegenerative agents |
| IL89835A0 (en) * | 1988-04-11 | 1989-12-15 | Merck & Co Inc | Substituted azetidinones,their preparation and pharmaceutical compositions containing them |
| IL99658A0 (en) * | 1990-10-15 | 1992-08-18 | Merck & Co Inc | Substituted azetidinones and pharmaceutical compositions containing them |
| GB9421816D0 (en) * | 1994-10-29 | 1994-12-14 | Smithkline Beecham Plc | Novel compounds |
| BR9510420A (pt) * | 1994-12-22 | 2004-04-20 | Smithkline Beecham Plc | Azetidin-2-onas substituìdas para o tratamento de aterosclerose |
-
1996
- 1996-06-20 NZ NZ311684A patent/NZ311684A/xx unknown
- 1996-06-20 EA EA199800109A patent/EA199800109A1/ru unknown
- 1996-06-20 BR BR9609445A patent/BR9609445A/pt unknown
- 1996-06-20 CZ CZ974221A patent/CZ422197A3/cs unknown
- 1996-06-20 AU AU63050/96A patent/AU708032B2/en not_active Ceased
- 1996-06-20 AP APAP/P/1997/001161A patent/AP728A/en active
- 1996-06-20 WO PCT/EP1996/002765 patent/WO1997002242A1/fr not_active Ceased
- 1996-06-20 CA CA002225627A patent/CA2225627A1/fr not_active Abandoned
- 1996-06-20 SK SK1784-97A patent/SK178497A3/sk unknown
- 1996-06-20 EP EP96922030A patent/EP0840725A1/fr not_active Withdrawn
- 1996-06-20 KR KR1019970709952A patent/KR19990028630A/ko not_active Withdrawn
- 1996-06-20 IL IL12265096A patent/IL122650A0/xx unknown
- 1996-06-20 TR TR97/01762T patent/TR199701762T1/xx unknown
- 1996-06-20 PL PL96324240A patent/PL324240A1/xx unknown
- 1996-06-20 HU HU9901153A patent/HUP9901153A3/hu unknown
- 1996-06-20 CN CN96196661A patent/CN1197452A/zh active Pending
- 1996-06-20 JP JP50477297A patent/JP2002515852A/ja active Pending
- 1996-06-28 MA MA24298A patent/MA23922A1/fr unknown
- 1996-06-28 PE PE1996000496A patent/PE8998A1/es not_active Application Discontinuation
-
1997
- 1997-12-30 NO NO976158A patent/NO976158L/no unknown
- 1997-12-31 OA OA70172A patent/OA10648A/en unknown
-
1998
- 1998-01-07 MX MX9800186A patent/MX9800186A/es unknown
- 1998-01-28 BG BG102214A patent/BG102214A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SK178497A3 (en) | 1998-07-08 |
| CA2225627A1 (fr) | 1997-01-23 |
| AP728A (en) | 1999-01-29 |
| WO1997002242A1 (fr) | 1997-01-23 |
| CZ422197A3 (cs) | 1998-06-17 |
| HUP9901153A2 (hu) | 1999-08-30 |
| OA10648A (en) | 2002-09-25 |
| AP9701161A0 (en) | 1998-01-31 |
| HUP9901153A3 (en) | 1999-11-29 |
| NZ311684A (en) | 2000-04-28 |
| EP0840725A1 (fr) | 1998-05-13 |
| BR9609445A (pt) | 1999-04-06 |
| KR19990028630A (ko) | 1999-04-15 |
| JP2002515852A (ja) | 2002-05-28 |
| NO976158L (no) | 1998-02-25 |
| TR199701762T1 (xx) | 1998-05-21 |
| PL324240A1 (en) | 1998-05-11 |
| EA199800109A1 (ru) | 1998-10-29 |
| PE8998A1 (es) | 1998-03-20 |
| CN1197452A (zh) | 1998-10-28 |
| IL122650A0 (en) | 1998-08-16 |
| AU6305096A (en) | 1997-02-05 |
| MA23922A1 (fr) | 1996-12-31 |
| MX9800186A (es) | 1998-07-31 |
| BG102214A (en) | 1998-08-31 |
| NO976158D0 (no) | 1997-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU708032B2 (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
| US6071899A (en) | Azetidinone derivatives for the treatment of atherosclerosis | |
| US5990102A (en) | Substituted azetidin-2-ones for treatment of atherosclerosis | |
| JP2000509049A (ja) | アテローム性動脈硬化症の治療用アゼチジノン誘導体 | |
| KR100338171B1 (ko) | 저콜레스테롤형증제로서유용한치환된아제티디논화합물 | |
| US5744467A (en) | Sulfur-substituted azetidinone compounds useful as hypocholesterolemic agents | |
| JP2000505063A (ja) | アテローム性動脈硬化症の治療のためのアゼチジノン化合物 | |
| FR2476089A1 (fr) | Nouveaux derives substitues de 7-oxo-4-thia-1-azabicyclo(3.2.0) hept-2-ene, procede et composes intermediaires pour leur production, composition pharmaceutique les contenant et leur application a la lutte contre des infections bacteriennes | |
| JP2000509063A (ja) | アテローム性動脈硬化症の治療用アゼチジノン誘導体 | |
| EP0869943A1 (fr) | Derives de beta-lactame monocycliques utilises dans le traitement de l'atherosclerose | |
| JPH05279367A (ja) | β−ラクタム誘導体の製法 | |
| RU2214409C2 (ru) | N-фениламидные и n-пиридиламидные производные, способ их получения и содержащие их фармацевтические композиции | |
| JPS58134074A (ja) | 抗菌剤、その製法及びそれを含む医薬組成物 | |
| JPH0780840B2 (ja) | ４，４‐ジアルキル‐２‐アゼチジノン類の製造法 | |
| EP0658550A2 (fr) | Sels d'acide aminé de composés de tétrazole ayant une activité antihypercholestérolémique et procédés pour leur préparation | |
| FR2552763A1 (fr) | Nouveaux derives du carbapeneme, leur preparation et leur utilisation comme medicaments | |
| JPH04117382A (ja) | １―メチルカルバペネム誘導体及びその製法 | |
| KR20000065040A (ko) | 아테롬성동맥경화증치료를위한아제티디논유도체 | |
| MXPA98008924A (en) | Azetidinone derivatives for deeterosclero treatment |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |